Research Topic · Peer-Reviewed

Anticoagulant Therapy

Anticoagulant therapy is a critical aspect in hematology and oncology research, which is aimed at preventing thromboembolic events in cancer patients. Cancer patients are highly susceptible to developing deep vein thrombosis (DVT) and pulmonary embolism (PE), which can result in fatal outcomes. Therefore, anticoagul…

Curated from this journal's research 📚 5 peer-reviewed articles cited Cited 13× across the literature 🔖 ISSN 2372-6601 🗓 Reviewed June 2026

Overview

Anticoagulant therapy is a critical aspect in hematology and oncology research, which is aimed at preventing thromboembolic events in cancer patients. Cancer patients are highly susceptible to developing deep vein thrombosis (DVT) and pulmonary embolism (PE), which can result in fatal outcomes. Therefore, anticoagulant therapy is essential in controlling and prophylaxis of these events. Anticoagulant agents, such as heparin, enoxaparin, and warfarin, are used to prevent the formation and propagation of blood clots. These agents have different mechanisms of action, including inhibition of thrombin, factor Xa, or vitamin K, which are essential factors in the clotting cascade. Low molecular weight heparins (LMWHs), such as enoxaparin, are the preferred anticoagulant agents in cancer patients due to their higher bioavailability and longer half-life, resulting in a more predictable anticoagulant effect. Moreover, LMWHs have demonstrated efficacy in reducing the risk of recurrent venous thromboembolism (VTE) in cancer patients, with no significant difference in bleeding complications compared to other anticoagulant agents. The management of anticoagulant therapy in cancer patients requires a delicate balance between the prevention of thromboembolic events and reduction of the risk of bleeding complications. Therefore, close monitoring of the patient's coagulation profile is essential to ensure appropriate dosing and prevent adverse events. In conclusion, anticoagulant therapy is a critical aspect of hematology and oncology research that aims to prevent thromboembolic events in cancer patients. The use of LMWHs, such as enoxaparin, is preferred due to their higher bioavailability and longer half-life, resulting in a more predictable anticoagulant effect. Close monitoring of the patient's coagulation profile is essential in the management of anticoagulant therapy to ensure appropriate dosing and prevent adverse events.

Research published in this journal

5 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 5 articles above have been cited 13 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Anticoagulant Therapy, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Hematology and Oncology Research (ISSN 2372-6601).

Journal editorial board
Jayadev Manikkam Umakanthan · United States Shuaiying Cui · United States Benedetto Sacchetti · Italy

This page summarises published research for orientation; it is not medical or professional advice.